Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > You all say wow! Dan the man,

<< Previous

Bullboard Posts

Next >>

Comment by WalkOverTheStrton Feb 24, 2021 5:09pm

244 Views

Post# 32653359

RE:You all say wow! Dan the man,

Below is my take on the CEO (whether these points can be placed on his shoulders):

+ Added solid leaders: CMO & partner team
+ Ran successful outcome PH1 & PH2 trial

- Constant pre-covid delays in PH2 / unable to meet deadlines
- Poor planning of mgmt equity exercising / to PH2B results
- Releasing a sub par PR for PH2B and not having a follow on same day analysts Q&A
- Two raises at near identical valuations after multiple positive PRs (outstanding PH2 results, China deal) / increased shareholder potential base (sr CA exchange, r/s).
- Limited progress on other pipeline candidates

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter